By Soumya Ranjan Mankind Pharma, Bajaj Finance, Bharat Coking Coal and Pidilite have reported their Q3 results. Here are a few stocks to watch ahead of Wednesday’s trading session.
MANKIND PHARMA
In the third quarter of this year, Mankind Pharma’s net profit increased 7.5% to ₹408.7 crore from ₹380.2 crore in the same period last year. EBITDA rose 12.7% to ₹919.6 crore from ₹816.2 crore, while revenue expanded 11.5% to ₹3,567 crore from ₹3,198 crore YoY. The EBITDA margin for the company was 25.8%, up from 25.5% during the same time last year.
BAJAJ FINANCE
Net Interest Income (NII) increased 20.6% to ₹11,318 crore from ₹9,383 crore YoY, while gross non-performing assets (NPA) was 1.21% as of December 31. Bajaj Finance recorded a net profit of ₹4,066 crore for the year, down 5.6% from ₹4,308 crore YoY.
FIRSTSOURCE SOLUTIONS LIMITED
For the third quarter, Firstsource Solutions Limited recorded a net profit of ₹120 crore, a 33% decrease from the previous quarter’s ₹179.5 crore. However, its income increased 6.6% from ₹2,314.6 crore QoQ to ₹2,467 crore. For FY 2025–2026, the company announced an interim dividend of ₹5.50 per share.
BHARAT COKING COAL
In contrast to a net profit of ₹425 crore in the same quarter previous year, Bharat Coking Coal reported a net loss of ₹23 crore in Q3.
PIDILITE INDUSTRIES LTD
Pidilite Industries recorded a net profit of ₹623.84 crore for the third quarter, exceeding the CNBC-TV18 poll estimate of ₹608 crore and up 11.9% from ₹557 crore during the same period last year.
TRIVENI TURBINE LTD
In Q3, Triveni Turbine Ltd.’s net profit was ₹92.1 crore, down 0.3% year over year from ₹92.4 crore in the same period prior year. Due to improved execution throughout the quarter, revenue increased dramatically by 24% YoY to ₹624 crore from ₹503.4 crore.
Read:
Disclaimer: This narrative is solely intended for educational reasons. The opinions and suggestions expressed above are not those of the Times of Dalal Street, but rather those of specific analysts or broking firms. Before making any financial decisions, we suggest investors to consult with qualified specialists.